Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A novel HDAC8 inhibitor H7E exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant M üller glia activation and oxidative stress
In this study, we investigated the protective effects and cellular mechanisms of H7E, a novel small molecule inhibits HDAC8, using in vitro and in vivo glaucoma-like models. Importantly, H7E mitigated extracellular MMP-9 activity and MCP-1 levels in glutamate- or S100B-stimulated reactive Müller glia. In addition, H7E inhibited the upregulation of inflammation- and proliferation-related signaling pathways, particularly the ERK and JNK MAPK pathways. Under conditions of oxidative damage, H7E prevents retinal cell death and reduces extracellular glutamate released from stressed Müller glia. In a mouse model of NMDA-induced...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 5, 2024 Category: Drugs & Pharmacology Authors: Liang-Huan Wu Yu-Wen Cheng Fan-Li Lin Kai-Cheng Hsu Mong-Heng Wang Jing-Lun Yen Tsung-Jen Wang Tony Eight Lin Yi-Chien Liu Wei-Jan Huang George Hsiao Source Type: research

A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients
Biomed Pharmacother. 2024 Apr 4;174:116537. doi: 10.1016/j.biopha.2024.116537. Online ahead of print.ABSTRACTChronic Lymphocytic Leukemia (CLL) patients have a defective expression of the proapoptotic protein p66Shc and of its transcriptional factor STAT4, which evoke molecular abnormalities, impairing apoptosis and worsening disease prognosis and severity. p66Shc expression is epigenetically controlled and transcriptionally modulated by STAT4; epigenetic modifiers are deregulated in CLL cells and specific histone deacetylases (HDACs) like HDAC1, are overexpressed. Reactivation of STAT4/p66Shc expression may represent an a...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 5, 2024 Category: Drugs & Pharmacology Authors: Sara Rossi Vanessa Tatangelo Maria Dichiara Stefania Butini Sandra Gemma Simone Brogi Silvia Pasquini Martina Cappello Fabrizio Vincenzi Katia Varani Ludovica Lopresti Margherita Malchiodi Chiara Carrara Alessandro Gozzetti Monica Bocchia Giuseppe Marotta Source Type: research

Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension
Biomed Pharmacother. 2024 Apr 3;174:116505. doi: 10.1016/j.biopha.2024.116505. Online ahead of print.ABSTRACTPulmonary arterial hypertension (PAH) was a devastating disease characterized by artery remodeling, ultimately resulting in right heart failure. The aim of this study was to investigate the effects of canagliflozin (CANA), a sodium-glucose cotransporter 2 inhibitor (SGLT2i) with mild SGLT1 inhibitory effects, on rats with PAH, as well as its direct impact on pulmonary arterial smooth muscle cells (PASMCs). PAH rats were induced by injection of monocrotaline (MCT) (40 mg/kg), followed by four weeks of treatment with ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Xiaojun Chen Xing Yu Guili Lian Huibin Tang Yan Yan Gufeng Gao Bangbang Huang Li Luo Liangdi Xie Source Type: research

Free fatty acid receptor 4 (FFA4) activation attenuates obese asthma by suppressing adiposity and resolving metaflammation
Biomed Pharmacother. 2024 Apr 2;174:116509. doi: 10.1016/j.biopha.2024.116509. Online ahead of print.ABSTRACTObese asthma is recognized to have different asthma phenotypes. N-3 polyunsaturated fatty acids (PUFAs) have shown beneficial effects in obesity and metabolic syndrome. Free fatty acid receptor 4 (FFA4, also known as GPR120) is a receptor for n-3 PUFAs. In the present study, we investigated whether FFA4 activation ameliorates high-fat diet (HFD)-induced obese asthma. We investigated whether FFA4 activation ameliorates obese asthma using an FFA4 agonist, compound A (CpdA), in combination with FFA4 wild-type (WT) and ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: So-Eun Son Jung-Min Koh Dong-Soon Im Source Type: research

Proposal for considerations during human iPSC-derived cardiac organoid generation for cardiotoxicity drug testing
Biomed Pharmacother. 2024 Apr 3;174:116511. doi: 10.1016/j.biopha.2024.116511. Online ahead of print.ABSTRACTHuman iPSC-derived cardiac organoids (hiPSC-COs) for cardiotoxicity drug testing via the variety of cell lines and unestablished protocols may lead to differences in response results due to a lack of criteria for generation period and size. To ensure reliable drug testing, it is important for researchers to set optimal generation period and size of COs according to the cell line and protocol applied in their studies. Hence, we sought to propose a process to establish minimum criteria for the generation duration and ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Sang Woo Lee MyeongJin Song Dong-Hun Woo Gi Seok Jeong Source Type: research

GPX4, ferroptosis, and diseases
Biomed Pharmacother. 2024 Apr 2;174:116512. doi: 10.1016/j.biopha.2024.116512. Online ahead of print.ABSTRACTGPX4 (Glutathione peroxidase 4) serves as a crucial intracellular regulatory factor, participating in various physiological processes and playing a significant role in maintaining the redox homeostasis within the body. Ferroptosis, a form of iron-dependent non-apoptotic cell death, has gained considerable attention in recent years due to its involvement in multiple pathological processes. GPX4 is closely associated with ferroptosis and functions as the primary inhibitor of this process. Together, GPX4 and ferroptosi...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Wangzheqi Zhang Yang Liu Yan Liao Chenglong Zhu Zui Zou Source Type: research

Industrial-produced lemon nanovesicles ameliorate experimental colitis-associated damages in rats via the activation of anti-inflammatory and antioxidant responses and microbiota modification
In this study, we explore the protective effects of industrially produced lemon vesicles (iLNVs) in a rat model of IBD. Characterization of iLNVs reveals the presence of small particles less than 200 nm in size and a profile of bioactive compounds enriched in flavonoids and organic acids with known beneficial properties. In vitro studies on human macrophages confirm the safety and anti-inflammatory effects of iLNVs, as evidenced by the reduced expression of pro-inflammatory cytokines and increased levels of anti-inflammatory markers. As evidenced by in vivo experiments, pre-treatment with iLNVs significantly alleviates sym...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Vincenza Tinnirello Maria Grazia Zizzo Alice Conigliaro Mariangela Tabone Nima Rabienezhad Ganji Adele Cicio Carlo Bressa Mar Larrosa Francesca Rappa Giuseppe Vergilio Roberta Gasparro Alessia Gallo Rosa Maria Serio Riccardo Alessandro Stefania Raimondo Source Type: research

Equisetum arvense standardized dried extract hinders age-related osteosarcopenia
Biomed Pharmacother. 2024 Apr 3;174:116517. doi: 10.1016/j.biopha.2024.116517. Online ahead of print.ABSTRACTAge-associated osteosarcopenia is an unresolved syndrome characterized by the concomitant loss of bone (osteopenia) and skeletal muscle (sarcopenia) tissues increasing falls, immobility, morbidity, and mortality. Unbalanced resorption of bone in the remodeling process and excessive protein breakdown, especially fast type II myosin heavy chain (MyHC-II) isoform and myofiber metabolic shift, are the leading causes of bone and muscle deterioration in the elderly, respectively. Equisetum arvense (EQ) is a plant traditio...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Laura Salvadori Martina Paiella Beatrice Castiglioni Maria Laura Belladonna Tommaso Manenti Catia Ercolani Luca Cornioli Nausicaa Clemente Andrea Scircoli Roccaldo Sardella Leonardo Tensi Andrea Astolfi Maria Letizia Barreca Sara Chiappalupi Giulia Gentil Source Type: research

Epigallocatechin-3-gallate confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis, apoptosis, and autophagy via modulation of 14-3-3 η
In conclusion, EGCG pretreatment attenuated ferroptosis, apoptosis, and autophagy by mediating 14-3-3η and protected cardiomyocytes against MIRI.PMID:38574620 | DOI:10.1016/j.biopha.2024.116542 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Tie Hu Fa-Jia Hu Huang Huang Ze-Yu Zhang Ya-Mei Qiao Wen-Xiong Huang Yi-Cheng Wang Xin-Yi Tang Song-Qing Lai Source Type: research

Memantine suppresses the excitotoxicity but fails to rescue the ataxic phenotype in SCA1 model mice
Biomed Pharmacother. 2024 Apr 3;174:116526. doi: 10.1016/j.biopha.2024.116526. Online ahead of print.ABSTRACTSpinocerebellar ataxia type 1 (SCA1) is a debilitating neurodegenerative disorder of the cerebellum and brainstem. Memantine has been proposed as a potential treatment for SCA1. It blocks N-methyl-D-aspartate (NMDA) receptors on neurons, reduces excitotoxicity and decreases neurodegeneration in Alzheimer models. However, in cerebellar neurodegenerative diseases, the potential value of memantine is still unclear. We investigated the effects of memantine on motor performance and synaptic transmission in the cerebellum...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Olga S Belozor Alex Vasilev Alexandra G Mileiko Lyudmila D Mosina Ilya G Mikhailov Darius A Ox Elizaveta B Boitsova Andrey N Shuvaev Anja G Teschemacher Sergey Kasparov Anton N Shuvaev Source Type: research

Antinociceptive effect of LMH-2, a new sigma-1 receptor antagonist analog of haloperidol, on the neuropathic pain of diabetic mice
This study evaluates the antiallodynic and antihyperalgesic effects of LMH-2, a new haloperidol (HAL) analog that acts as sigma-1 receptor (σ1 R) antagonist, in diabetic mice using a model of neuropathic pain induced by chronic hyperglycemia. Additionally, we compared its effects with those of HAL. Hyperglycemia was induced in mice by nicotinamide-streptozotocin administration (NA-STZ, 50-130 mg/kg). Four weeks later, mechanical allodynia was assessed using the up-down method, and hyperalgesia was evoked with formalin 0.5%. We evaluated antiallodynic and antihyperalgesic effects of LMH-2 (5.6-56.2 mg/kg), HAL (0.018-0.18 ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Rosa Ventura-Mart ínez Guadalupe Esther Ángeles-López Diana Gonz ález-Ugalde Tania Dom ínguez-Páez Gabriel Navarrete-V ázquez Ruth Jaimez Myrna D éciga-Campos Source Type: research

Novel clinical phenotypes, drug categorization, and outcome prediction in drug-induced cholestasis: Analysis of a database of 432 patients developed by literature review and machine learning support
CONCLUSIONS: We identified novel associations among DIC manifestations and disclosed novel DIC subphenotypes with specific clinical and chemical traits. The developed predictive DIC outcome model could facilitate DIC prognosis in clinical practice and drug categorization.PMID:38574623 | DOI:10.1016/j.biopha.2024.116530 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Marta Moreno-Torres Ernesto L ópez-Pascual Anna Rapisarda Guillermo Quint ás Annika Drees Inger-Lise Steffensen Thomas Luechtefeld Eva Serrano-Candelas Marina Garcia de Lomana Domenico Gadaleta Hubert Dirven Mathieu Vinken Ramiro Jover Source Type: research

Targeting liver and adipose tissue in obese mice: Effects of a N-acylethanolamine mixture on insulin resistance and adipocyte reprogramming
In conclusion, we demonstrated that this olive oil-derived NAE mixture is a valid nutritional strategy to counteract IR and obesity acting on liver-AT crosstalk, restoring both hepatic and AT function and metabolism.PMID:38574624 | DOI:10.1016/j.biopha.2024.116531 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: S Melini A Lama F Comella N Opallo F Del Piano C Annunziata M P Mollica M C Ferrante C Pirozzi G Mattace Raso R Meli Source Type: research

Efficient combination of radiotherapy and CAR-T - A systematic review
Biomed Pharmacother. 2024 Apr 3;174:116532. doi: 10.1016/j.biopha.2024.116532. Online ahead of print.ABSTRACTChimeric antigen receptor T (CAR-T) cell therapy, a groundbreaking immunotherapy. However, it faces formidable challenges in treating solid tumors, grappling with issues like poor trafficking, limited penetration, and insufficient persistence within the tumor microenvironment (TME). CAR-T cells are engineered to express receptors that target specific cancer antigens, enhancing their ability to recognize and eliminate cancer cells. This review paper explores the intricate interplay between CAR-T therapy and radiother...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Wojciech Szlasa Aleksandra Sztuder Agnieszka Kaczmar-Dybko Adam Maciejczyk Jaros ław Dybko Source Type: research

Biomedicine and pharmacotherapeutic effectiveness of combinatorial atorvastatin and quercetin on diabetic nephropathy: An in vitro study
CONCLUSION: Nevertheless, there is currently no existing literature that reports on the role of QCT as a combination renoprotective drug with statins in the context of diabetic nephropathy. Hence, these findings suggest that atorvastatin and quercetin may have clinical potential in treating diabetic nephropathy.PMID:38574626 | DOI:10.1016/j.biopha.2024.116533 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 4, 2024 Category: Drugs & Pharmacology Authors: Haleema Shahin Dh Rokeya Sultana Ashwini Prabhu Pavan S R Sourav Mohanto Vetriselvan Subramaniyan Source Type: research